All News

infx.pneumonia.jpg

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

Jack Cush, MD

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

Read Article
PSA%20026.jpg

Long-Term Benefits of Ixekizumab in Psoriatic Arthritis

Jack Cush, MD

The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well. 

Read Article
SPA.spectrum.jpg

SPARTAN ACR20 Recommendations on Spondyloarthritis

Jack Cush, MD

SPARTAN has compiled a list of presentations and sessions worth seeing if you are interested in ankylosing spondylitis, spondyloarthritis and related disorders.

Read Article
podcast logo

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Jack Cush, MD

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article
pssfing.jpg

Abatacept in Early Systemic Sclerosis (ASSET study)

Jack Cush, MD

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).

Read Article
PSS.hands_.Raynauds.jpg (keep)

FDA Invites Patient Input on Systemic Sclerosis Drug Development

Jack Cush, MD

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.

Read Article
PsA.Hands_.jpg

Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis

Jack Cush, MD

The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.

Read Article
colitis.jpg

Vedolizumab Promising in Immune-Related GI Events

Jack Cush, MD

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Read Article
@JYazdanyMD @UWRheum @r_burmester Black, et al - cont'd 277 atypical femur fx events Risk increased w longer duration of bisphosphonate use Risk decreased after bisphosphonate discontinuation Asians had a higher risk than Whites. #ACR20 #ACRambassador

Rheum Cat rheum_cat ( View Tweet)

4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6, cirrhosis NNH 1000 5.LoDoCo2: colchicine prevents MACE: NNT 36 6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ: NNH 600

k dao KDAO2011 ( View Tweet)

Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity to learn about side-effects" of a drug we commonly use. Low-dose MTX assoc. with small-mod. elevated risk of transaminitis, infection, anaemia & skin cancer. #ACR20 @RheumNow https://t.co/hNS600Pndr
Mrinalini Dey DrMiniDey ( View Tweet)
How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdanyMD Year-in-Review #ACR20 @rheumnow

Eric Dein ejdein1 ( View Tweet)

Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need

Links:

Peter Nash drpnash ( View Tweet)

Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response

Links:

Peter Nash drpnash ( View Tweet)

Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat

Links:

Peter Nash drpnash ( View Tweet)

#ACR20 year in review @JYazdanyMD CIRT trial showing that MTX pneumonitis occurs but is very (very) rare. @RheumNow @jeffsparks @DanielHSolomon https://t.co/UbD4mhHBzq
Richard Conway RichardPAConway ( View Tweet)
Exciting to hear about 5 trials for #GCA 1. ABAGART (#Abatacept) 2. METOGIA (#tocilizumab vs MTX) 3. SELECT (#upadacitinib) 4. MAVRILIMUMAB (#gmcsf i) 5. TiTIAN (#secukinumab) ⁦@VasculitisFound⁩ #vasculitis #vcrc https://t.co/DVvG5Ekfu9
KenWarringtonMD MdWarrington ( View Tweet)
RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0

Links:

Dr. John Cush RheumNow ( View Tweet)

Incidence & Risk VTE Among Pts RA Enrolled in Upadacitinib Trial Program https://t.co/zCuWHZXV4h #VTE #Upadacitinib balanced VTE across trial programme in the expected 0.5-0.8/100 pt yrs range - past VTE & BMI risk factors, no mention COX2s - is VTE Jak2 effect or class effect?

Links:

Peter Nash drpnash ( View Tweet)

Safety of nintedinib (NIN)in PSS-ILD - 576 PSS pts given NIN 150 mg bid or PBO x52wks. Dose lowered to 100 mg bid for AE. Diarrhea seen in 76% of NIN and 32% in PBO (d/c in 6.9% & 0.3%). Dose reduction in 48% & 12%. RCT discontinuation in 16% & 8.7% https://t.co/v5NxwlHu37

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×